Company news
Intensity Therapeutics, Inc. (NASDAQ:INTS) news
Every Intensity Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
Intensity Therapeutics : to Announce Second Quarter 2026 Financial Results on August 11, 2026
August 4, 2026
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Tri...
July 15, 2026
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
April 15, 2026
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
March 27, 2026
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
March 24, 2026
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
March 12, 2026
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
March 6, 2026
Intensity Therapeutics Announces Reverse Stock Split
February 13, 2026
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
January 13, 2026
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
December 11, 2025
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
December 5, 2025
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
December 4, 2025
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 6, 2025
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
October 31, 2025
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers ...
October 30, 2025
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
September 10, 2025
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
August 12, 2025
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2025
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
August 4, 2025
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral N...
June 30, 2025
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
June 11, 2025
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
June 11, 2025
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumo...
June 11, 2025
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology ...
May 29, 2025
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to...
May 28, 2025
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Ini...
May 6, 2025
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Ini...
May 6, 2025
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
April 25, 2025
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
March 13, 2025
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE...
January 28, 2025
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
January 10, 2025
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from...
December 12, 2024
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
November 21, 2024
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial...
November 18, 2024
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Soc...
November 8, 2024
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Pr...
October 31, 2024
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 8, 2024
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tiss...
July 9, 2024
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
May 15, 2024
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Ra...
May 10, 2024
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
April 2, 2024
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
March 26, 2024